Related Experiment Video
Updated: Feb 7, 2026

Evaluation of Coronary Flow Reserve After Myocardial Ischemia Reperfusion in Rats
Published on: June 28, 2019
Reducing mitochondrial dysfunction through combination therapy to limit ischemia-reperfusion injury in male DCD rats
Zachary Kiernan1, Gina Labate1, Qun Chen2,3
1Division of Cardiothoracic Surgery, Department of Surgery, Virginia Commonwealth University, Richmond, VA, United States.
Introduction:
Two predominant pathways contribute to ischemia reperfusion injury (IRI) following donation after circulatory death (DCD): mitochondrial permeability transition pore (MPTP) opening and Calpain-1 (CPN1) activation. Each pathway has established inhibitors; Cyclosporine A (CyA) and MDL-28170 (MDL), respectively, which are effective in modulating IRI in a DCD heart with 25 min of warm ischemia time (WIT). We studied the effect of co-administering CyA and MDL during reperfusion on infarct size and graft function in DCD rat hearts with extended WIT of 35 min.
Methods:
Male rats were exposed to 35 min of warm ischemia followed by 90 min of reperfusion. During reperfusion, hearts were given either 0.5 mM of CyA, 10 mM of MDL, or mixed CyA and MDL. Cardiac function and coronary flow rates were monitored throughout reperfusion and infarct size at the end of reperfusion.
Results:
Infarct size in hearts treated with mixed CyA + MDL (31.59 ± 7.1%) was less than that of MDL-treated hearts (33.26 ± 4.3%) but larger than CyA-treated hearts (25.49 ± 5.9%). Graft function and coronary flow rates were variable amongst groups. CyA-treated hearts had more profound infarct size reduction when compared to MDL, and no additional synergistic effect was seen with combination treatment.
Discussion:
Our results indicate that MPTP opening contributes significantly to the development of IRI in DCD hearts.
Insights
Cyclosporine A (CyA) effectively reduced infarct size in donation after circulatory death (DCD) rat hearts with extended warm ischemia. Combination therapy with MDL-28170 (MDL) showed no synergistic benefit, indicating mitochondrial permeability transition pore opening is a key factor in DCD heart IRI.
Area of Science:
- Cardiology
- Transplantation Biology
- Ischemia Reperfusion Injury Research
Background:
- Donation after circulatory death (DCD) hearts face ischemia reperfusion injury (IRI).
- Mitochondrial permeability transition pore (MPTP) opening and Calpain-1 (CPN1) activation are key IRI pathways.
- Inhibitors Cyclosporine A (CyA) and MDL-28170 (MDL) modulate IRI in DCD hearts with shorter warm ischemia times (WIT).
Purpose of the Study:
- To investigate the effect of co-administering CyA and MDL during reperfusion on infarct size and graft function in DCD rat hearts with extended WIT (35 min).
Main Methods:
- Male rats underwent 35 min warm ischemia followed by 90 min reperfusion.
- Hearts received CyA, MDL, or a combination of both during reperfusion.
- Cardiac function, coronary flow, and infarct size were assessed.
Main Results:
- CyA treatment resulted in a significant reduction in infarct size (25.49%) compared to MDL (33.26%).
- Combined CyA + MDL treatment (31.59%) did not show synergistic benefits over CyA alone.
- Graft function and coronary flow rates were variable across groups.
Conclusions:
- MPTP opening is a significant contributor to IRI in DCD hearts.
- CyA is more effective than MDL in reducing infarct size in this model.
- Combined therapy offers no additional advantage over CyA monotherapy.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Limiting Reactant
Animal Mitochondrial Genetics
Export of Mitochondrial and Chloroplast Genes
The Number e as a Limit
Infertility in Males

